Image guided SBRT for multiple liver metastases with ExacTrac Adaptive Gating by Rubio, Carmen et al.
reports of practical oncology and radiotherapy 2 2 ( 2 0 1 7 ) 150–157
Available  online  at  www.sciencedirect.com
ScienceDirect
jo ur nal home p ag e: ht tp : / /www.e lsev ier .com/ locate / rpor
Original research article
Image  guided  SBRT  for  multiple  liver  metastases
with ExacTrac® Adaptive  Gating
Carmen Rubioa,∗, Ovidio Hernando-Requejoa, Daniel Zucca Apariciob,
María  ALlona Krauel c, Mercedes López Gonzaleza, Juan María Pérezb,
Emilio  Sánchez Saugara, Pedro Fernández Letónb
a Departments of Radiation Oncology, HM Hospitales, Spain
b Departments of Medical Physics, HM Hospitales, Spain
c Departments of Radiodiagnosis, HM Hospitales, Spain
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 2 August 2015
Received in revised form 8 June 2016
Accepted 23 July 2016






a  b  s  t  r  a  c  t
Aim: To report the outcome and toxicity of sequential stereotactic body radiotherapy (SBRT)
for  multiple liver metastases in patients treated with ExacTrac Adaptive Gating.
Background: In selected patients with a limited number of liver metastases, SBRT has been
evaluated as a safe and effective treatment, with minimal toxicity and high rates of local
control.
Materials and methods: From April 2008 to October 2013, 21 patients with multiple (3–14)
liver metastases (n = 101) were treated sequentially with SBRT at our institution. Maximum
tumor diameter was 7.5 cm. Prior to treatment, internal markers were placed inside or near
the  tumor. CT or PET-CT simulation was used for the definition of gross tumor volume
(GTV). Median planning target volume was 32.3 cc (3.6–139.3 cc). Treatment consisted of 3
fractions (12–20 Gy/fraction) or 5 fractions (10 Gy/fraction), prescribed to the 90–95% of the
PTV volume. Daily intra-fraction image guidance was performed with ExacTrac Adaptive
Gating. Regular follow-up included CT or PET-CT imaging.
Results: After a median of 23.2 months, the estimated local control rate was 94.4%, 80.6%,
65%  and 65% after 1, 2, 3 and 4 years; the median overall survival was 62 months (95% CI49.12–74.87) and the actuarial survival reached at 60 months was 57.6%. The univariate data
analysis revealed that only primary histology other than colorectal adenocarcinoma was
shown as an independent significant prognostic factor for local control (p = 0.022). Number
of  treated metastases did not modify significantly the overall survival (p = 0.51). No toxicity
ient with chest wall pain) and no radiation-induced liver disease werehigher than G3 (1 patobserved.
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Conclusions: Sequential SBRT with ExacTrac Adaptive Gating for multiple liver metastases can
be  considered an effective, safe therapeutic option, with a low treatment-related toxicity.
Excellent rates of local control and survival were obtained.
















































he liver is a common site of metastases from most solid
alignancies. Improvements in systemic therapy, including
hemotherapy and molecularly targeted agents, have led to
mproved survival, although they rarely eradicate metas-
ases in a permanent way. In an “oligo-metastatic” scenario
patients with single or limited metastases), local therapies
ay improve overall survival.1 For colorectal liver metastases,
esection series have yielded 5-year survival rates of 50–60%,2
eading to a cure of selected cases. However, most patients
ith liver metastases are unfit for surgery because of unfa-
orable tumor factors or their poor general conditions, and
reatment strategies focusing on effective local treatment may
e indicated after proper patient selection.
Historically, radiation therapy has had a limited role in
he treatment of hepatic metastasis because of the low tol-
rance of the liver to radiation. A major concern is the risk
f radiation-induced liver disease (RILD).3 However, the liver
beys the parallel architecture model of radiobiology and the
isk of RILD is proportional to the mean dose of radiation deliv-
red to normal liver tissue; therefore, it becomes safe to treat
mall hepatic lesions with high doses, limiting the mean dose
o normal liver.4
In the past decade, improvements in tumor imaging, radi-
tion therapy planning, delivery, and motion management,
ave contributed to the development of stereotactic body
adiation therapy (SBRT). Intensification of tightly focused
adiation to small lesions, while significantly limiting dose to
he surrounding tissues, in either a single or limited number of
ose fractions have resulted in the delivery of a highly biolog-
cal effective dose. SBRT requires a high level of accuracy, and
ecommendations and treatment quality control guidelines
ave been established.5,6
For liver SBRT, integration of imaging (CT, MRI, PET-CT) is
equired in order to properly define the metastases, as is highly
onformed dosimetry to further minimize radiation dose to
ealthy liver and surrounding tissues. Due to uncertainty of
iver positioning during the breathing, the effectiveness and
afety of SBRT depends on the accuracy to treat a moving
rgan. Various image-guided methods, the use of internal
arkers, breathing control and intra-fraction control of tumor
osition (Gating or Tracking) increase SBRT precision, allow-
ng the delivery of cytotoxic high dose to the metastases, while
aintaining whole-liver doses within acceptable limits.7,8
The feasibility and potential utility of SBRT in selected
atients with liver metastases, has been evaluated with
ncouraging results. SBRT has resulted as a safe and effective
reatment, with minimal toxicity and high rates of local
ontrol.9–16 Therefore, it can be considered a noninvasive
reatment to deliver ablative treatments.17–19 Most of theretrospective and prospective clinical experiences and stud-
ies of liver metastases (using high-dose SBRT) have generally
selected patients with a limited number of lesions. However,
there are also patients with more  than 3 liver metastases
or patients with liver oligo-progression that in the course of
their disease could be treated safely and benefit from abla-
tive local treatments with sequential SBRT, thus improving
their metastatic sites, decreasing morbidity and prolonging
survival.
2.  Aim
The purpose of the present article is to report the efficacy
and safety of high-dose sequential SBRT in oligo-metastatic
patients with multiple liver metastases (3 or more), not eli-
gible for surgery. Patients were treated with Novalis ExacTrac
Adaptive Gating, based on the accuracy of the irradiation of
the lesions in a selected area of the respiratory cycle, with an
intra-fraction control of the tumor position guided by internal
markers.
3.  Materials  and  methods
3.1.  Eligibility
From April 2008 to October 2013, 21 oligo-metastatic patients
with multiple liver lesions (3 or more), not eligible for surgery
after discussion in a multidisciplinary tumor-board, were
treated with high-dose SBRT, with Novalis ExacTrac Adaptive
Gating, at our institution.
Pretreatment evaluation in all patients consisted of physi-
cal examination, laboratory tests, including blood counts and
liver enzymes, computed tomography (CT) scan of the tho-
rax and abdomen with i.v. contrast and in selected patients
whole body positron emission tomography (PET) with [18F]-
fluorodeoxyglucose (FDG) on a dedicated combined PET/CT
scanner.
Inclusion criteria for the analysis were: patients with 3
or more  liver metastases considered not suitable for surgery,
because of being technically or medically inoperable or
because of patient refusal; minimum age 18 years; Karnofsky
Performance Status ≥70; no evidence of untreated or progres-
sive gross disease outside the liver; maximum tumor diameter
less than 8 cm,  normal liver volume >1000 cm3 and adequate
liver function (total bilirubin <3 mg/dL, albumin >2.5 g/dL, nor-
mal prothrombin time (PT)/partial thromboplastin time (PTT),
aspartate aminotransferase (AST) and alanine amynotrans-
ferase (ALT) less than 3 times the upper limit of normal).
Chemotherapy was allowed 14 days before or after SBRT and
written informed consent was required.
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Fig. 1 – Treatment plan for a patient treated with stereotactic body radiation therapy for multiple liver metastasis.
Visualization of dose distribution on the planning target volumes.3.2.  SBRT
Prior to treatment, in order to use them as a point of reference
and measure for ExacTrac Adaptive Gating, 1–3 fiducial inter-
nal markers (Visicoil®0.75 mm × 30 mm)  were implanted into
the liver, guided by CT scan, with local anesthesia and using
a preloaded needle.
CT or [18F]-FDG PET-CT scans, with i.v. contrast, were per-
formed with breath-holding, (3 mm slice thickness), and with
external markers located on the patient’s surface. The external
markers were used as a reference of position and later track-
ing with the infrared cameras of the ExacTrac system. Patients
were immobilized with a custom-formed vacuum cushion or
wing board. No 4D CT scan was performed.iPlan (BrainlabTM)
v3 and v4 were used for contouring and planning. Planning
CT images were in some cases co-registered with magnetic
resonance imaging (MRI) or [18F]-FDG PET-CT for a better iden-
tification of the gross tumor volume (GTV). The clinical target
volume (CTV) was defined as equal to the GTV. The planning
target volume (PTV) was generated from either the GTV-CTV
by adding an overall isotropic margin of 5 mm,  for attending
the set-up margin (3 mm)  and the internal margin (2 mm).  No
internal target volume (ITV) was defined.
SBRT (Fig. 1) was delivered using multiple coplanar beams
and 3-D highly conformal dosimetry.6 IMRT  (Intensity modu-
lated radiation therapy) was performed in 5 patients (23.8%)
to avoid adjacent organs at risks (OARs).
The prescripted dose was 36 Gy, 45 Gy or 60 Gy in 3 fractions
of 12 Gy, 15 Gy or 20 Gy, respectively, separated by at least 48 h,
or 50 Gy in 5 daily fractions, prescribed to the 90–95% of the
PTV volume. Previously reported critical dose volume modelwas applied to fulfill the constraints for organs at risk (OAR):
V15 Gy (volume receiving 15 Gy) < (total liver volume < 700 cm3)
for healthy liver, D0.1 cm3 for spinal cord <18 Gy (dose at a
volume of 0.1 cm3 should be <18 Gy), V15 Gy <35% for both kid-
neys, V21 Gy <1% for the duodenum, small bowel, esophagus,
and stomach, V30 Gy <1% for the heart and D30 cm3 <30 Gy
for the ribs. In the case of an overlap between the PTV and
the duodenum or stomach, the priority was given to the OAR.
Due to liver dose tolerance limitation, no more  than 4 liver
metastases were treated at the same time.
Patients were treated with SBRT in a Novalis (BrainlabTM),
a 6MV mono-energetic LINAC, adapted to stereotactic treat-
ments. Intra-fraction image  guided radiation therapy (IGRT)
was performed with the Novalis ExacTrac Adaptive Gating.
During patient set-up, the external markers on the patient’s
skin were tracked with the ExacTrac infrared cameras for auto-
matic patient positioning (guided by the Novalis robotic 6D
coach), and for tracking the respiratory cycle of the patient
during the treatment. Three pairs of ExacTrac stereoscopic X-
rays localized the internal marker subrogated to the external
markers, in the different phases of the respiratory cycle (inspi-
ration, gating reference level and exhalation). The location
of the internal marker was correlated with the PTV isocen-
ter, in order to quantify the tumor motion and determined a
gated area (“beam on area”) for irradiation. Beam on area never
exceeded 2 mm above and 2 below the gating reference level,
due to the prior established PTV isotropic margin of 5 mm,
taking into account the 3 mm set-up margin. Intra-fraction
stereoscopic X-rays were performed during the treatment, in
order to verify the position of the markers and the accuracy of
the irradiation during the “beam on area”.


















































Table 1 – Patient characteristics.
Age
Mean 64.14 (Range 42–80)
Sex
Male 12 (57%) Female 9 (43%)
Number of lesions per patient
3 6 patients (28.6%)
4 8 patients (38.1%)
5 3 patients (14.3%)
6 1 patient (4.8%)
7 1 patient (4.8%)
9 1 patient (4.8%)
14 1 patient (4.8%)
No. of internal markers
1 6 patients (28.6%)
2 13 patients (61.9%)
3 2 patients (8.5%)
Histology
Colorectal Adenocarcinoma 13 (61.9%)
Breast cancer 2 (9.5%)
Pancreas cancer 2 (9.5%)
Others 4 (19.1%)
Lesion size
<5 cm 86 (85.1%)
>5 cm 15 (14.9%)
Extra-hepatic disease
No 19 (90.5%) Yes 2 (9.5%)
Systemic treatments
Chemotherapy 1 line 7 (33.3%)
Chemotherapy 2 lines 8 (38.1%)
Chemotherapy ≥3 lines 6 (28.6%)
Table 2 – Treatment characteristics.
Lesions Fractions Total Dose Dose per fraction
24 (23.8%) 3 36 Gy 12 Gy
45 (44.6%) 3 45 Gy 15 Gy
1 (1%) 3 48 Gy 16 Gy
3 (3%) 3 54 Gy 18 Gyreports of practical oncology and 
.3.  Study  end  points  and  follow-up
he primary end-point for this retrospective study was to
ssess infield local control. Secondary end points were to
efine the value of CT and [18F]-FDG PET-TC for the assess-
ent of tumor response, radiation treatment-related toxicity,
verall survival and progression free survival.
Patients were monitored by physical examination and a
asal blood, coagulation and serum liver parameters were
nalyzed at the beginning of the SBRT. During treatment, all
atients were monitored for acute treatment related toxic-
ty. After conclusion of SBRT, patient’s follow-up included an
nterview, clinical exams and blood tests one month after the
reatment and every 3 months.
Acute and late toxicity were scored by the Common Ter-
inology Criteria for Adverse Events (CTCAE version 3.0).
ny increase in grade from baseline was considered toxicity
elated to the treatment.
Assessment of tumor response was based evaluated, with
T-iv contrast scan, 3 months after radiotherapy and every
–6 months, based on European Organization for Research
nd Treatment of Cancer Response Evaluation Criteria In
olid Tumors (EORTC-RECIST) criteria version 1.1.20,21 Com-
lete response (CR) was defined as disappearance of all target
esions; partial response (PR) as at least a 30% decrease in the
um of diameters of target lesions; and progressive disease
PD) as at least a 20% increase in the sum of diameters of target
esions. Progressive disease was scored depending on whether
t was intra- or extrahepatic. In selected patients with more
han 4 liver metastases or sequential SBRT treatments[18F]-
DG PET-TC- iv contrast scans were performed at 3 months,
 months and 12 months for assessment of tumor response
as based also on Choi criteria and PERCIST criteria.22
.4.  Statistical  considerations
ll enrolled patients were included in the statistical evalu-
tion. V.20 Statistical Packege for Social Science (SPSS Inc.
hicago, IL), was used for the statistical analysis. Actuarial
C and OS curves were generated by using the Kaplan–Meier
ethod and Log Rank Test was used for the univariate com-
aratives. When differences were found, Cox proportional
azards regression was used to measure the HRs. The results
ere considered statistically significant when p ≤ 0.05.
.  Results
his ongoing study included 21 enrolled patients with 101
iver metastases from solid tumors treated between April 2008
nd October 2013. The median follow-up was 23.2 months
range 3–66 m).  Baseline patients and treatment characteris-
ics are summarized in Tables 1 and 2. No patient received
ny prior directed liver therapies. The mean D95% was 97.9%
range 88.8–100%) for PTV. The Mean GTV diameter was 3.4 cm
1.14–7.5 cm). The Mean PTV volume was 32.6 cc (3.6–139 cc).
he Mean liver volume was 1.344.3 cc (range 747–2.223 cc).
Seventy-seven lesions (70.4%) received 48–60 Gy
3 × 15–20 Gy BED10, >120 Gy), 6 lesions (5.9%) 50 Gy (5 × 10 Gy,22 (21.8%) 3 60 Gy 20 Gy
6 (5.9%) 5 50 Gy 10 Gy
BED10 = 100 Gy) and 24 metastasis (23.8%) 36 Gy (3 × 12 Gy,
BED10 < 100 Gy).
Three patients (14.3%) were treated with one single SBRT
course, and 18 patients (85.7%) received a median of 2 sequen-
tial SBRT treatments (range: 2–8). The median number of
lesions treated each course was 2 (range: 1–4). Median time
between two consecutive SBRT treatments was 8 months
(range: 3–29), and the elapsed time between the first and the
last treatment was 15 months (range 3–51).
4.1.  Local  control
The radiographic crude response rate of the radiated lesions
was: 42.6% complete response (n = 43), 29.7% partial response
(n = 30) and 6.9% stable disease (n = 7). In-field progression was
observed in 21 lesions (20.8%), mean time 19 months (Table 3).Actuarial local control rates for treated lesions were 94.4%,
80.6%, 65% and 65% at 12, 24, 36 and 48 months respectively,
the median for local control has not been reached yet (Fig. 2).
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Table 3 – Patterns of treatment response.
In-field response Lesions no./(%)
Complete response 43 (42.6%)
Partial response 30 (29.7%)
Stable disease 7 (6.9%)
Progressive disease 21 (20.8%)
Fig. 2 – In-field local control after SBRT for multiple liver
Table 4 – Patterns of failure.
Site of failure Patients no./%
No progression after SBRT 4 (19%)
Progressive disease after SBRT 17 (81%)
Intra-hepatic progression 12 (70.5%)
Extra-hepatic progression 5 (29.5%)
Fig. 4 – Progression free survival after SBRT for multiple
liver metastases.metastases.
The univariate analysis showed that only metastases from
colorectal adenocarcinoma showed significantly poor local
control when compared with other primary tumors (p = 0.022;
HR 0.26), having 3.8 more  probabilities of local relapse (Fig. 3).
Fig. 3 – Local control according to type of lesion, colorectal
adenocarcinoma versus other primary tumors.4.2.  Assessment  of  tumor  response
A sub-analysis of 20 liver metastasis on complete response
after 2 years of follow up were evaluated, both by CT and
[18F]-FDG-PET-TC scans. Imaging studies were performed at
3 months, 6 months and 12 months after SBRT. At contrast-
enhanced CT scans, both size (cm) and attenuation coefficient
(UH) of the lesions were evaluated. At PET-TC scans [18F]-FDG
uptake (SUV) of the lesion was evaluated. The comparative of
both techniques, showed that at 3 and 6 months [18F]-FDG-
PET-CT was much more  sensitive to detect complete response
(100% with RECIST 1.1 criteria), than CT (50% with RECIST 1.1
criteria and 90% with Choi criteria), and at 12 months the
sensitivity of CT to assess response increased, reaching 80%
following RECIST 1.1 criteria and 100% Choi criteria.
4.3.  Progression  free  survival
At the time of the analysis, 4 patients (19%) were free of disease
and 17 patients (81%) had progressive disease, 12 (70.5%) with
intra-hepatic progression and 5 (29.5%) with extra-hepatic dis-
ease (Table 4). The median progression free survival was 22
months (95% CI 6.1–37.8). Estimated progression free survival
at 12, 24 and 36 months was 76.2%, 39.1% and 16.8%, respec-
tively (Fig. 4).
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t the time of analysis, 14 patients (66.6%) had died, of these, 9
64.3%) had died of disease-specific causes, whereas 5 (35.7%)
f other causes.
The median OS rate was 62 months (95% CI 49.12–74.87).
ctuarial survival at 12, 24, 36 and 60 months was 95%, 85.7%,
0.7% and 57.6%, respectively (Fig. 5).
Number of treated metastases did not modify significantly
he overall survival (p = 0.51) nor did the other analyzed factors
age, sex, histology of the primary tumor, SBRT doses, number
f SBRT treatments, other metastases, or systemic treatment).
.5.  Toxicity
he treatment was very well tolerated with only grade 1 acute
ide effects, predominantly mild fatigue during the days of
reatment. Due to the puncture procedures for the implan-
ation of internal markers, one case of liver peri-hepatic
ematoma grade 1 was reported.
No relevant long-term complications (grade 4 or 5) were
eported. Only 2 patients experienced late toxicity with grade 1
nd 3 chronic chest wall pain that regressed with conservative
reatment.
.  Discussion
he liver is a common site of metastases from most solid
alignancies and in many  cases it is the only site. Chemother-
py and new molecularly targeted agents, have led to
mproved survival, although surgical resection is still consid-
red the gold standard treatment to eradicate liver metastases.
owever, most patients with liver metastases are unfit for
urgery because of unfavorable tumor factors or their poortherapy 2 2 ( 2 0 1 7 ) 150–157 155
general conditions and in a “oligo-metastatic” scenario, with
single or limited metastases, local ablative therapies may
improve overall survival.
Historically, radiation therapy has had a limited role in the
treatment of liver metastasis, but in the last decade, advances
in tumor imaging, radiation therapy planning, delivery, and
motion management, have contributed to improve the accu-
racy of the treatments and to the development of SBRT, thus
allowing the ablative irradiation of liver lesions and limiting
the dose to healthy liver and other surrounding organs.
However, for moving lesions such as liver lesions, prob-
lems with accuracy still remain and assessment of tumor
motion in liver can be approached in different ways. Quan-
tification of tumor motion can be measured and an ITV
(internal target volume) can be deduced using a 4D-CT scan
during the different respiratory phases. However, it has been
found that respiratory motion can often range up to 50 mm,
meaning the ITV deduced from extreme respiratory phases is
sometimes overestimated, resulting in too much healthy liver
tissue included in the PTV and unnecessarily irradiated.10–13
In the liver the major dose-limiting concern is the risk of
radiation-induced liver disease (RILD), proportional to the
mean dose of radiation delivered to normal liver tissue and
this considerably limits the number of patients that can
benefit from SBRT due to the number or size of their liver
lesions.
We retrospectively analyzed a subgroup of patients treated
of multiple (3 or more)  liver metastases with ExacTrac Adap-
tive Gating, irradiating the tumor during a selected phase of
the respiratory cycle, and verifying tumor position in real time
with ExacTrac stereoscopic X-rays in an effort to decrease the
PTV margin and save as much healthy liver and surrounding
organs as possible.
Previous works have demonstrated the efficacy and secu-
rity of SBRT for the treatment of liver metastases (Table 5). The
University of Heidelberg9 reported one of the earliest prospec-
tive studies to use single fraction SBRT (dose, 14 to 26 Gy) for
the treatment of liver metastases, with local control rate of
66% at 18 months.
Rochester University10 reported the experience with SBRT
in 69 patients with a total of 174 metastases (20 patients with
colorectal liver metastases) treated with a median total dose
of 48 Gy in 8 or more  fractions. Local control rate was of 76%
and 57% at 10 and 24 months respectively.
A prospective, multicenter phase I/II study11 evaluated 47
patients with 63 liver metastases, dose was escalated from
36 Gy to 60 Gy in three fractions, in 6 Gy increments, without
dose-limiting toxicity [11]. Lesions with maximum diameter of
3 cm or less achieved a 2-year local control of 100% compared
with 77% for lesions greater than 3 cm (p = 0.015).
Chang12 reported the results of the study of a pooled
patient cohort treated with SBRT for colorectal liver metas-
tases (1–4 lesions, 1–6 fractions of SBRT), including 65 patients
with 102 lesions from 3 institutions. The median follow up was
1.2 years. Total dose, dose per fraction and BED all correlated
with local control. The estimated dose range needed for 1-year
local control >90% was 46–52 Gy in 3 fractions.
Scorsetti13 in the phase II trial reported 61 patients with
76 lesions treated with 3 fractions up to 75 Gy; they observed
excellent local control and survival at 1 year (both >80%).
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Table 5 – Clinical studies in the literature studying SBRT in liver metastases.
Ref. Design N◦ patients SBRT dose Toxicity Outcomes







Katz, 2005 Retrospective 69 48 Gy (in 8 or more
fractions)
No grade ≥3 toxicity 10-mo, LC 76%
24-mo, LC 57%
Rusthoven, 200911 Phase I-II 47 Dose escalation 45–60 Gy (in
3 fractions)
No  RILD







65  46–52 Gy (in 3 fractions) Grade ¾ toxicity: 3% 1-yr, LC >90%
Scorsetti, 201313 Phase II 61 75 Gy (in 3 fractions) No RILD






153  37.5 ± 8.2 Gy (in 5 ± 3
fractions)
Grade ¾ toxicity: 3% 1-yr, LC 62%
1-yr OS 51%
Hernando, 201318 Retrospective 47 36–60 Gy (in 3 fractions) No grade ≥3 toxicity 2-yr, LC 87.3%
 Gy pe
ctionAndratschke, 201516 Retrospective 74 5–12.5
3–5 fra
In a recent multicenter database from 4 academic medical
centers in the United States14 the total dose was 37.5 ± 8.2 Gy
in 5 ± 3 fractions, with a median follow-up of 25 months, they
reported on 153 patients (363 tumors) a local control rate of
62% with one-year survival of 51%. Grade 3 and 4 toxicity was
observed in 3% of patients.
We  previously reported our initial experience on the treat-
ment of lung and liver lesions with Gating SBRT; in the liver
metastases set,15 47 patients with 74 liver metastases (48 colo-
rectal liver metastases) where treated. Dose prescription was
36–45–60 Gy in three fractions. Median follow up was 13.6
months and 2-year local control rate was 87.3%. No Grade 3
toxicity was described.
Andratschke,16 in a recent publication reported the experi-
ence with SBRT in 74 patients with 91 liver metastases, treated
with 5–12.5 Gy per fraction in 3–5 fractions, with a median
follow-up of 15 months. They reported a local control rate of
74.7%, 48.3% and 48.3% at 1, 2 and 3 years. Only the BED to
GTV was a significant factor for local control in multivariate
analysis, with 100% of local control in those receiving minimal
BED > 120 Gy to GTV. Median overall survival was 25 months,
GTV volume was a significant prognostic factor for overall sur-
vival in multivariate analysis. No acute Grade 3–5 and no late
Grade 4–5 toxicity was observed.
Here we report a long-term follow-up group of patients with
multiple liver metastases (3 or more)  treated with sequential
SBRT from 2008 to 2013 (median follow up: 23.2 months). Sim-
ilar to other published studies, the local control was very high,
94.4%, 80.6%, 65% and 65% at 12, 24, 36 and 48 months, respec-
tively, even considering that we  treated more  lesions (71.4% of
the patients had more  than 3 metastasis) and with a consider-
able size (14.9% > 5 cm). Local control was mainly influenced by
lesion size and radiation dose in other studies. In our patients
we only found colorectal adenocarcinoma histology as a pre-
dictive factor for local control in univariate analysis.In our sub-analysis for assessment of tumor response in 20
liver metastasis on complete response after 2 years of follow
up, with CT and [18F]- PET-TC scans, we  found that 18-FDG-
PET-CT was much more  sensitive to detect complete responser fraction (in
s)
No  grade ≥3 toxicity 1-yr, LC 74.7%
2-yr, LC 48.3%
3-yr, LC 48.3%
than CT on the first 6 months, probably due to early radiolog-
ical changes induced by ablative doses of irradiation, and in
certain patients [18F]-FDG PET-CT may be necessary for the
confirmation of a possible local control, although this data
need to be confirmed in further studies.
As expected, when we analyzed patients with multiple liver
metastases, our crude PFS rate was low 19%, only 4 patients
were free of disease after SBRT. The median PFS was 22 was
months. While 29.5% of the patients developed metastases in
other organs, the majority (70.5%) progressed with new liver
metastases that were treated sequentially with new courses
of SBRT whenever possible. Eighteen patients (85.7%) received
a median of 2 sequential SBRT treatments (range: 2–8) and the
median time between two consecutive SBRT treatments was
8 months (range: 3–29), reaching long periods of time between
SBRT courses (median of 15 months, range 3–51).
The overall survival reached a median time of 62 months,
with estimated survival at 5 years of 57.6%. This overall sur-
vival is longer than achieved in other studies, this could be
explained by the selection of patients for sequential SBRT
treatments that were performed during their disease evolu-
tion. To our knowledge, this sequential SBRT courses have not
been referred previously for the management of liver metas-
tases.
Although further studies also need to be done to confirm
these results, the toxicity that we found with sequential SBRT
treatments for multiple liver lesions are very acceptable and
similar to those published in the literature and no relevant
long-term complications (grade 4 or 5) were reported. The
implantation of internal markers in the liver did not repre-
sent a major concern and gave us the accuracy for treating
these patients with the Exactrac Adaptive Gating.
6.  ConclusionsOur findings confirm that SBRT provides an effective local
ablation with low toxicity profile even in patients with mul-
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an be prolonged with sequential SBRT treatments. Exac-
rac Adaptive Gating with intra-fraction tumor motion control
ave demonstrated to be a safe and accurate SBRT technique
or liver metastases treatment. Prospective controlled trials
re needed to confirm this results.
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